Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News

Dow Jones11-14

By Josh Beckerman

Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering.

The stock gained 60% to $3.38 in the regular session Wednesday after its Tuesday earnings report. In after-hours trading, shares were recently down 24% to $2.58.

On Tuesday, Calidi reported a wider net loss and said it "continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies." Loss per share narrowed, reflecting a higher number of shares outstanding.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 13, 2024 18:58 ET (23:58 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483647848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 07:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483647848","market":"hk","top_or_hot":-1,"title":"Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<p>\n  Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. \n</p>\n<p>\n  The stock gained 60% to $3.38 in the regular session Wednesday after its Tuesday earnings report. In after-hours trading, shares were recently down 24% to $2.58. \n</p>\n<p>\n  On Tuesday, Calidi reported a wider net loss and said it \"continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies.\" Loss per share narrowed, reflecting a higher number of shares outstanding. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 18:58 ET (23:58 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 07:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n  Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. \n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDI","symbol_name":"CALIDI BIOTHERAPEUTICS INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483647848","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483647848","pubTimestamp":1731542280,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering.The stock gained 60% to $3.38 in the regular session Wednesday after its Tuesday earnings report. In after-hours trading, shares were recently down 24% to $2.58.On Tuesday, Calidi reported a wider net loss and said it \"continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies.\" Loss per share narrowed, reflecting a higher number of shares outstanding.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDI":"CALIDI BIOTHERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Calidi Biotherapeutics因第三季度报告而飙升，因股票发行消息而回落","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDI":0.9},"content_text":"By Josh Beckerman \n\n\n  Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. \n\n\n  The stock gained 60% to $3.38 in the regular session Wednesday after its Tuesday earnings report. In after-hours trading, shares were recently down 24% to $2.58. \n\n\n  On Tuesday, Calidi reported a wider net loss and said it \"continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies.\" Loss per share narrowed, reflecting a higher number of shares outstanding. \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 18:58 ET (23:58 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483647848"}